Felsher DW - Search Results

1

Definition of an enhanced immune cell therapy in mice that can target stem-like lymphoma cells.

Contag CH, Sikorski R, Negrin RS, Schmidt T, Fan AC, Bachireddy P, Felsher DW, Thorne SH. Contag CH, et al. Among authors: felsher dw. Cancer Res. 2010 Dec 1;70(23):9837-45. doi: 10.1158/0008-5472.CAN-10-2650. Epub 2010 Oct 8. Cancer Res. 2010. PMID: 20935221 Free PMC article.

2

Conditional animal models: a strategy to define when oncogenes will be effective targets to treat cancer.

Giuriato S, Rabin K, Fan AC, Shachaf CM, Felsher DW. Giuriato S, et al. Among authors: felsher dw. Semin Cancer Biol. 2004 Feb;14(1):3-11. doi: 10.1016/j.semcancer.2003.11.002. Semin Cancer Biol. 2004. PMID: 14757531 Review.

3

The E47 transcription factor negatively regulates CD5 expression during thymocyte development.

Yang Y, Contag CH, Felsher D, Shachaf CM, Cao Y, Herzenberg LA, Herzenberg LA, Tung JW. Yang Y, et al. Proc Natl Acad Sci U S A. 2004 Mar 16;101(11):3898-902. doi: 10.1073/pnas.0308764101. Epub 2004 Mar 4. Proc Natl Acad Sci U S A. 2004. PMID: 15001710 Free PMC article.

4

MYC inactivation uncovers pluripotent differentiation and tumour dormancy in hepatocellular cancer.

Shachaf CM, Kopelman AM, Arvanitis C, Karlsson A, Beer S, Mandl S, Bachmann MH, Borowsky AD, Ruebner B, Cardiff RD, Yang Q, Bishop JM, Contag CH, Felsher DW. Shachaf CM, et al. Among authors: felsher dw. Nature. 2004 Oct 28;431(7012):1112-7. doi: 10.1038/nature03043. Epub 2004 Oct 10. Nature. 2004. PMID: 15475948 Free article.

5

Tumor dormancy and MYC inactivation: pushing cancer to the brink of normalcy.

Shachaf CM, Felsher DW. Shachaf CM, et al. Among authors: felsher dw. Cancer Res. 2005 Jun 1;65(11):4471-4. doi: 10.1158/0008-5472.CAN-05-1172. Cancer Res. 2005. PMID: 15930260 Review.

6

Getting at MYC through RAS.

Bachireddy P, Bendapudi PK, Felsher DW. Bachireddy P, et al. Among authors: felsher dw. Clin Cancer Res. 2005 Jun 15;11(12):4278-81. doi: 10.1158/1078-0432.CCR-05-0534. Clin Cancer Res. 2005. PMID: 15958607 No abstract available.

7

Conditionally MYC: insights from novel transgenic models.

Arvanitis C, Felsher DW. Arvanitis C, et al. Among authors: felsher dw. Cancer Lett. 2005 Aug 26;226(2):95-9. doi: 10.1016/j.canlet.2004.10.043. Epub 2004 Dec 16. Cancer Lett. 2005. PMID: 16039948 Review.

8

MYC can induce DNA breaks in vivo and in vitro independent of reactive oxygen species.

Ray S, Atkuri KR, Deb-Basu D, Adler AS, Chang HY, Herzenberg LA, Felsher DW. Ray S, et al. Among authors: felsher dw. Cancer Res. 2006 Jul 1;66(13):6598-605. doi: 10.1158/0008-5472.CAN-05-3115. Cancer Res. 2006. PMID: 16818632 Free article.

9

Conditional transgenic models define how MYC initiates and maintains tumorigenesis.

Arvanitis C, Felsher DW. Arvanitis C, et al. Among authors: felsher dw. Semin Cancer Biol. 2006 Aug;16(4):313-7. doi: 10.1016/j.semcancer.2006.07.012. Epub 2006 Jul 21. Semin Cancer Biol. 2006. PMID: 16935001 Review.

10

Sustained regression of tumors upon MYC inactivation requires p53 or thrombospondin-1 to reverse the angiogenic switch.

Giuriato S, Ryeom S, Fan AC, Bachireddy P, Lynch RC, Rioth MJ, van Riggelen J, Kopelman AM, Passegué E, Tang F, Folkman J, Felsher DW. Giuriato S, et al. Among authors: felsher dw. Proc Natl Acad Sci U S A. 2006 Oct 31;103(44):16266-71. doi: 10.1073/pnas.0608017103. Epub 2006 Oct 20. Proc Natl Acad Sci U S A. 2006. PMID: 17056717 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

179 results

Search Page

Filters